US FDA Moves Homeopathic Drug Enforcement To Risk-Based Approach
Executive Summary
Products with routes of administration other than oral and topical or intended to be used for the prevention or treatment of serious or life-threatening diseases and conditions will be among those prioritized for enforcement and "regulatory actions," draft guidance notes.
You may also be interested in...
US Courts Reject Reinstating FDA's Homeopathic Drug Policy As Challenge To Change Proceeds
Decisions in US Circuit and District courts for District of Columba are on complaint by Rx drug firm MediNatura, but should resonate for OTC homeopathic firms as well as all businesses across the sector. MediNatura appealed district ruling rejecting request for injunction against FDA’s withdrawal of 1988 homeopathic CPG.
FDA Appropriation Targets $100,000 To Find Safe CBD Level In Supplements
Rep. McNerneny's amendment calls for process that would follow steps FDA used in exercising enforcement discretion on natural products that contain levels of an approved drug ingredient, with red yeast rice most notable. But critics of FDA's VMS industry oversight don't see McNerney's amendment as effective not only for strengthening FDA's overall regulation but also for solving its CBD problem.
FDA Reprimands Snake Venom Seller For Pain Claims Amid Opioid Crisis
Nutra Pharma’s Nyloxin claims to relieve cancer pain and potentially help treat opioid addiction, among others, mark its products as unapproved new drugs, FDA asserts in a warning letter that reflects its homeopathic enforcement approach proposed in late 2017. “Health fraud scams like these are inexcusable,” says FDA Commissioner Scott Gottlieb.